September 23, 2019
Novo Nordisk wins FDA’s approval for first oral GLP-1 treatment for type 2 diabetes
The U.S. Food and Drug Administration approved on Friday Novo Nordisk’s Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.